Newsletter Articles 2026

January ~ Mars Mission Medical Emergencies

NASA just successfully concluded its first medical evacuation from the ISS. A crew member experienced a serious health condition aboard the International Space Station, forcing the space agency to terminate the Crew-11 mission a month early and return all astronauts to Earth. This highlights a critical reality check on deep-space human health risks, emergency protocols, and life-support challenges—all essential for planning long Mars missions.

Thankfully, NASA has, and continues to develop, robust medical systems and contingency planning for Mars missions, where evacuation isn’t possible. Let’s do a quick review of the existing medical supplies and protocols aboard the ISS. Then look at what will be required for a Mars mission of 30-plus months.

The ISS carries a comprehensive, flight-certified system called Crew Health Care System (CHeCS). It’s designed to assist crews for months at a time, handle medical emergencies, and serve as a testbed for future deep-space missions. It integrates monitoring, diagnostics, treatment, and emergency response.

The ISS possesses crew-operated diagnostic and monitoring equipment, supplemented with real-time guidance from Earth-based physicians. The devices measure vital signs and provide physiological monitoring. Inventory includes blood pressure cuffs, pulse oximeters, digital thermometers, an electrocardiograph, respiratory rate monitor, and a portable ultrasound. Collectively, they allow for musculoskeletal trauma assessment, cardiac evaluation and abdominal exams.

On-board advanced life support and emergency equipment includes an automated external defibrillator (AED), oxygen delivery systems, a bag-valve mask for manual ventilation, airway management tools, and CPR restraint equipment to assist in microgravity conditions. According to NASA, ISS medical care is designed to stabilize for evacuation, not perform complex surgery in situ.

Because of the higher incidence of cosmic and solar radiation in Earth orbit, station pharmaceutical supplies are replaced on an ongoing basis. These include pain medications (acetaminophen, ibuprofen), antibiotics, anti-nausea, allergy, sleep aid and motion sickness drugs. ISS also keeps topical treatments, IV fluids and a limited number of injectable medications on hand. Trauma and emergency supplies, bandages and wound dressings, suturing kits, hemostatic agents, splints, burn treatments and eye irrigation tools round out the inventory.

ISS medical operations rely heavily on crew medical officers. They’re non-physician astronauts trained in emergency medicine. In turn, they rely heavily on decision support software, supplemented by real-time or delayed telemedicine under the auspices of flight surgeons at NASA’s Johnson Space Center.

The International Space Station’s medical system represents the most advanced healthcare ever deployed off Earth. Yet it still relies on rapid evacuation in a matter of hours or days. There is limited onboard decision authority. The afore-mentioned flight surgeons have the final sat in medical decisions. The system also relies heavily on resupply.

This is not the case for Mars missions. Mission-critical medical emergencies cannot be aided from Earth during a Mars transit. Any mission must rely on full medical autonomy for 30-plus months. The crew will have to diagnose, decide, and treat medical events independently. Decision support will be limited by 4-to-24-minute one-way communication delays.

Unlike on the ISS, evacuation might not even be possible. It’s probably not possible to carry enough fuel for a mid-outbound flight return to Earth. Conditions that triggered an evacuation on the ISS must be treated with procedures performed in-flight or on Mars.

Capabilities not present on the ISS will be needed. Beginning with crew medical officers with expanded diagnostic and treatment training. This could range from a full flight surgeon to a physician’s assistant with supplemental surgical training. AI-assisted onboard diagnostic and clinical software systems will augment the decision-making process. The mission must be equipped with advanced ultrasound with automated interpretation and a hand-held X-ray.

Mars medicine must replace Earth labs in miniature. Facilities will include compact blood analyzers, urinalysis and endocrine monitoring, continuous cardiovascular and neurological monitoring and radiation exposure dosimeters.

Pharmaceutical independence must be achieved through on-demand drug synthesis of select medications such as antibiotics and analgesics. Multi-year drug viability may not be possible otherwise. Medication expiration becomes a mission risk, not a logistics issue. Pharmaceutical precursors must be radiation-stable or maintained in a shielded environment.

Surgical capabilities, while limited, will include a sterile surgical enclosure and microgravity surgery protocol. Medical staff must be capable of appendectomies, wound debridement, abscess drainage, fracture stabilization, blood loss control, and advanced anesthesia. Interventions will prioritize lifesaving over perfection.

An often overlooked but mission-critical consideration will be dental care. According to NASA, dental issues are among the most common mission-ending risks. On Mars, such emergencies will have to be treated locally. Astronauts will need to perform fillings, extractions, and infection management. While NASA is not announcing the nature of the medical issue that forced the Crew-11 evacuation, it wouldn’t surprise me if it was for an inflamed root canal or an abscess.

I’ve discussed radiation Injury and cancer risk management in previous issues, but it bears repeating. Mars and the Mars transit will have no Earth magnetospheric protection. Astronauts will experience chronic deep-space exposure from cosmic rays and solar storms. Astronauts must be well-versed in radiation damage monitoring, acute radiation sickness treatment protocols and long-term cancer risk mitigation strategies. The spacecraft and surface habitats must both include, at a minimum, emergency radiation shelter.

Medical decisions may override mission objectives. Mars crews will have a clear medical authority hierarchy and pre-approved abort criteria. They’ll need ethical decision frameworks for distributing limited drug quantities. Those of us back on Earth must understand that this will be frontier medicine, not hospital medicine.

The ISS proves humans can live in space. A Mars mission must prove humans can diagnose without Earth, operate without rescue, treat without resupply, and endure without replacement. In other words, Mars medicine is a fundamentally new medical discipline.

Happy Reading!

Like what you just read? Share this issue with friends and encourage them to subscribe to receive free short stories, news about upcoming promotions and books by yours truly and other exciting Sci-Fi authors!

For further reading
https://abcnews.go.com/US/sick-astronaut-rest-crew-undock-iss-nasa/story?id=129200884
https://www.space.com/space-exploration/international-space-station/spacex-crew-11-astronauts-return-to-earth-after-1st-ever-medical-evacuation-of-iss
https://www.washingtonpost.com/technology/2026/01/15/splashdown-nasa-crew-11/
https://apnews.com/article/nasa-astronauts-space-crew-spacex-medical-california-13d6c5246a1afec200a811e6cfc049bf
https://www.nasa.gov/humans-in-space/chapea/
https://www.nasa.gov/image-article/tooth-extraction-practice/
https://www.nasa.gov/hrp/

February ~ A Surprise SpaceX Mission Shift?

On February 8, Elon Musk announced a revised goal for the SpaceX Starship program that marks a notable shift from his long-held focus on colonizing Mars.

In his Tweet, The SpaceX CEO publicly stated that the company is now prioritizing building a “self-growing city” on the Moon within the next decade. His rationale was that lunar missions offer more frequent launch windows, about every 10 days with a 2-day trip, enabling faster iteration and progress toward establishing an off-Earth settlement. By contrast, Mars launch windows occur every 26 months with a 6-month transit.

Musk said this lunar city goal could be achieved in under 10 years, whereas settlement of the Red Planet would likely take over 20 years. He still frames Mars colonization as part of the long-term plan. This pronouncement seems like a jarring redirection of SpaceX’s 20-year historical mission, until we examine some context.

Musk’s focus on establishing a self-supporting Martian city on appears to conflict with NASA’s goal to establish a permanent human presence on the Moon first, then applying lessons learned to future Mars colonization.

NASA projected Artemis III won’t launch before 2028 due to technical delays, including Starship development and Orion systems. Last Fall in response, acting Secretary of Transportation Sean Duffy reopened the Artemis III Human Landing System (HLS) lunar lander competition.

Starship has encountered testing gaps and timeline slips, pushing back demonstration flights and delaying readiness for a crewed landing. A key challenge is in-orbit fueling, critical for the spacecraft to transport astronauts and payloads from Earth orbit to the lunar surface. A technology SpaceX has not yet demonstrated

To reach the Moon with long-term projected payloads will require placing a methane fueling station in Earth orbit. Filling it is estimated to take up to 14 launches. Then a Starship is to dock and fill its fuel tanks, then head for a rectilinear halo lunar orbit. The space company is saying that test flights of the fuel transfer system won’t occur until 2027.

Bear in mind that SpaceX has yet to place a Starship lander in Earth orbit. Given that such a system has never been deployed, it’s easy to imagine that Duffy began to doubt that SpaceX could meet the 2028 timeframe for Artemis III.

NASA asked SpaceX and Blue Origin to submit accelerated HLS proposals by October 29, 2025. Other companies were also invited to respond to a broader Request for Information on lunar landing concepts around the same timeframe to explore whether other approaches could help the U.S. return astronauts to the Moon sooner.

NASA’s motivation to accelerate its Artemis III timeline is to stay ahead of other national space programs. China’s ambition is to land astronauts on the Moon by 2030. To meet its own 2028 goal, NASA is asking companies to propose “accelerated approaches,” even if that means reconfiguring existing designs or selecting alternative architectures.

Both SpaceX and Blue Origin submitted proposals by NASA’s deadline, laying out accelerated lunar lander development. Their submissions outline how each company could potentially deliver lunar landing capabilities faster than existing plans and help return astronauts to the Moon sooner.

The decision to reopen the lunar lander competition was discussed during NASA Administrator nominee Jared Isaacman’s second confirmation hearing on December 3, 2025. Isaacman was appointed on December 18. Once confirmed, the newly installed space agency chief advocated having both SpaceX and Blue Origin compete, stating that having them “right on their heels” is beneficial.

Crewed landers must satisfy rigorous safety, reliability, and mission assurance standards, often taking years of testing and validation. New or alternative concepts (whether from legacy aerospace firms or startups) must demonstrate maturity and risk mitigation strategies within tight timelines.

NASA is evaluating the plans from SpaceX and Blue Origin. According to industry reports, it is assembling review teams. Subject-matter experts will assess the proposals and determine viable paths forward, weighing factors such as schedule risk, technology maturity, and alignment with Artemis mission goals.

As of early February, NASA has not yet announced a final decision on the HLS competition. New, amended or extended HLS contracts to SpaceX, Blue Origin, or any other company have not been awarded. In the meantime, the established HLS agreements remain in place.

I’ve read conjecture about what SpaceX may be willing to do to deliver their Starship lander to meet NASA’s 2028 Artemis III deadline. Most intriguing was a scaled-down version of Starship. A smaller capacity lunar use version that wouldn’t require near-term fueling in Earth orbit.

It will be interesting to see if SpaceX can keep its grasp on Artemis III and IV, or if Blue Origin or some other space company will nudge them aside.

Happy Reading!

Like what you just read? Share this issue with friends and encourage them to subscribe to receive free short stories, news about the latest in Mars-related tech, and upcoming promotions and books by yours truly!

For further reading
https://futurism.com/space/elon-musk-change-city-moon
https://arstechnica.com/space/2026/02/has-elon-musk-given-up-on-mars/?utm_source=nl&utm_brand=ars&utm_campaign=aud-dev&utm_mailing=Ars_Orbital_021126&utm_medium=email&bxid=65b7bff8fa0b7a89580f3650&cndid=76333326&hasha=e8620ee793baaa68e769a8c40cbb61f1&hashb=3919d6f19501af75d0af661aa4cd9d6e1329b988&hashc=1bf82b64ba64698cf4b3a2ce3fd3e77e67d828f3872982df6524bf394df7dd57&esrc=bouncex-test&utm_content=Final&utm_term=ARS_OrbitalTransmission
https://www.reuters.com/science/us-seek-rival-bids-artemis-3-spacex-lags-nasa-chief-says-2025-10-20
https://payloadspace.com/duffy-opens-competition-to-speed-up-lunar-landing
https://spectrum.ieee.org/nasa-artemis-blue-origin-spacex
https://www.blueorigin.com/news/new-shepard-to-pause-flights
https://www.spacex.com/updates#moon-and-beyond
https://www.webpronews.com/starships-lunar-stumble-nasas-artemis-3-slips-to-2028-amid-refueling-hurdles
https://universemagazine.com/en/nasa-is-ready-to-terminate-its-contract-with-spacex-in-favor-of-blue-origin